These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24942375)

  • 41. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire.
    Haab F; Richard F; Amarenco G; Coloby P; Arnould B; Benmedjahed K; Guillemin I; Grise P
    Urology; 2008 Apr; 71(4):646-56. PubMed ID: 18313122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validity and reliability of patient selected goals as an outcome measure in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    Int Urogynecol J; 2011 Jul; 22(7):841-7. PubMed ID: 21279328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of the urinary sensation scale (USS).
    Coyne KS; Margolis MK; Hsieh R; Vats V; Chapple CR
    Neurourol Urodyn; 2011 Mar; 30(3):360-5. PubMed ID: 21254195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
    Bunyavejchevin S
    J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.
    Mamik MM; Rogers RG; Qualls CR; Morrow JD
    Int Urogynecol J; 2014 Oct; 25(10):1321-6. PubMed ID: 24562789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.
    Nixon A; Colman S; Sabounjian L; Sandage B; Schwiderski UE; Staskin DR; Zinner N
    J Urol; 2005 Aug; 174(2):604-7. PubMed ID: 16006914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The psychometric validation of the OAB family impact measure (OAB-FIM).
    Coyne KS; Matza LS; Brewster-Jordan J; Thompson C; Bavendam T
    Neurourol Urodyn; 2010 Mar; 29(3):359-69. PubMed ID: 19274760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urgency assessment in the evaluation of overactive bladder (OAB).
    Starkman JS; Dmochowski RR
    Neurourol Urodyn; 2008; 27(1):13-21. PubMed ID: 17671973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
    Xiao DD; Lv JW; Xie X; Jin XW; Lu MJ; Shao Y
    BMC Urol; 2016 Aug; 16(1):49. PubMed ID: 27503124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
    Rogers R; Bachmann G; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Nov; 19(11):1551-7. PubMed ID: 18685795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
    Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
    Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
    Gotoh M; Kobayashi T; Sogabe K
    Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing multiple dimensions of urgency sensation: The University of South Australia Urinary Sensation Assessment (USA
    Das R; Buckley J; Williams M
    Neurourol Urodyn; 2017 Mar; 36(3):667-672. PubMed ID: 26999753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The responsiveness of the OAB-q among OAB patient subgroups.
    Coyne KS; Matza LS; Thompson C; Jumadilova Z; Bavendam T
    Neurourol Urodyn; 2007; 26(2):196-203. PubMed ID: 17016794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.